Trial Condition(s):
Evaluation of Bay 59-8862 in Patients with Aggressive, Refractory Non-Hodgkin's Lymphoma
100389
Not Available
Not Available
Not Available
Almost two-thirds of lymphoma cases are Non-Hodgkin's Lymphomas (NHL). NHL is a malignant process that affects lymphoid cells found both in the lymph nodes and extranodally. Incidence and mortality rates from NHL are highest in developed countries. While many patients with aggressive NHL are curable with initial anthracycline-containing regimens, the majority of patients will relapse or prove refractory to initial therapy. The prognosis of patients with disease recurrence following a multidrug regimen is also limited. The current protocol is designed to test the safety and efficacy of BAY 59-8862 in patients with Aggressive Refractory Non-Hodgkin's Lymphoma.
- Measurable disease as defined by the presence of at least one measurable lesion - Failed at least one prior therapy or has achieved remission but has progressed or relapsed within 6 months of therapy - Life expectancy of at least 12 weeks - Adequate bone marrow, liver and kidney function
- Excluded medical conditions like: pre-existing neuropathy, active heart diseases or ischemia, serious infections, HIV infection, chronic hepatitis B or C, seizures, hypersensitivity to taxanes, organ transplants, some previous cancers - Excluded therapies and medications, previous and concomitant such as: anticancer chemotherapy or immunotherapy during the study or within 4 weeks prior to study entry; more than two prior anticancer chemotherapy regimens; radiotherapy during study or within 4 weeks prior to study entry; bone marrow transplant - Others: pregnant or breast-feeding patients; both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial; substance abuse, medical, psychological or social conditions that may interfere with the patient's participation
Locations | |
---|---|
Locations Investigative Site VANDOEUVRE-LES-NANCY, France, 54500 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site PIERRE BENITE, France, 69495 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Shreveport, United States, 71130-4228 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Groene Hilledijk, Netherlands | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Freiburg, Germany, 79106 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Maidstone, United Kingdom, ME16 9QQ | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Manhasset, United States, 11030-3876 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Valhalla, United States, 10595 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Miami Beach, United States, 33140 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Milwaukee, United States, 53226 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Memphis, United States, 38120 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Cleveland, United States, 44195 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Seattle, United States, 98195 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Chicago, United States, 60637 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Edmonton, Canada, T6G 1Z2 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site AMSTERDAM, Netherlands, 1081 HV | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Bronx, United States, 10467-2490 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Cambridge, United Kingdom, CB2 0QQ | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Berlin, Germany, 12200 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site PARIS, France, 75151 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Brooklyn, United States, 11235-3518 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site New Brunswick, United States, 08903-2681 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Syracuse, United States, 13210-2399 | Contact Us: E-mail: [email protected] Phone: Not Available |